• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Market for Generic Biologics – Issues, Trends, and Market Potential, 2nd edition, The

$2,500.00 – $5,000.00

Clear
SKU: KLI1170930 Category: Pharmaceuticals Market Research Pages: 150
  • Description
  • Table of Contents
  • Latest reports

Description

Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, are set to lose patent protection in the United States in 2005 and soon after. This opens up a market currently worth over $30 billion (and growing at over 10% per year) to generic competition, if—and it’s a big if—the regulatory hurdles for these generics can be overcome.

Biogeneric is a new term combining biologic and generic. Biopharmaceuticals are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies and nucleic acids such as DNA or RNA. Generic products are non-patented chemical and therapeutic equivalents of brand name drugs. However, given these two definitions, biogenerics are not technically generic biologics because there can be no true generic form of biologics in the traditional sense. The complex process of creating biologics and the complex nature of the molecules themselves make “equivalence” an inappropriate concept in the context of biologics. Hence, industry participants are struggling with what to call these hybrid forms of biologics that will be created by the generic companies.

The worldwide prescription generic drug market has stood the test of time and has endured numerous growing pains. However, it has evolved into a formidable and important participant in the complex world of health care. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals, as well, because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biogeneric promotion is favorable in the next five years.

This study is designed to provide a comprehensive look at the various strategies being used by select generic companies in exploring the emerging area of biogenerics, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biogenerics.

For purposes of study, Kalorama divided this market into biopharmaceuticals that have lost patent protection and biopharmaceuticals that will lose patent protection in the future. Projections were made based on the progress that is occurring within the generic arena in terms of capabilities, capital, interest, and development of biopharmaceuticals.

Kalorama has identified the biopharmaceuticals that have lost patent protection and are likely to be the first products that will be attempted by generic companies. Some of these products are relatively simple in structure (by biotech complexity) such as the insulins and human growth hormones, while others are extremely difficult to process. It is anticipated that the insulin and human growth hormones will be the first to be approved.

There are a number of biopharmaceuticals that will be targets for biogeneric development identified as potential targets for generic development. Many of these biopharmaceutical patents are due to expire in immediate future, over the next 4 years. Many of these products sport manufacturer sales of over $10 billion, presenting a ripe opportunity for generic manufacturers. However, because many of these products demonstrate sales of over $1 billion per year, it is anticipated that there will considerable resistance from the innovator companies in allowing generic capitalization and consequently approvals.

The information and analysis presented in this report are based on an extensive survey of senior management in the biogeneric drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 25 industry executives and product managers to validate and obtain expert opinion on current and future trends in the psychotherapeutic industry. Interviews were also used to confirm and/or adjust market size, as well as in formulating market projections.

All market data pertain to the world market at the manufacturers’ level. Data are expressed in current U.S. dollars. The geographic scope of the study is worldwide with particular emphasis on the United States.

Table of Contents

Chapter One: Executive Summary

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Trends Affecting the Market
  • Market Outlook

Chapter Two: Introduction and Overview

  • Biogenerics Overview
  • Biopharmaceutical Industry and the Approval Process
  • Genetic Engineering
  • Patent Approval
  • Regulations for Biopharmaceuticals
  • History of the Prescription Generic Pharmaceuticals Industry
  • History of the Generic Approval Process
  • Regulation of Prescription Generic Pharmaceuticals
  • Biopharmaceuticals
  • Areas of Treatment for Biopharmaceuticals

Chapter Three: Market Analysis—Biologics with Currently Expired Patents

  • Products
  • Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market

Chapter Four: Market Analysis: Biologics with Currently Active Patents

  • Products
  • Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market

Chapter Five: Issues and Trends

  • Overview
  • Regulatory and Legislative issues
  • Europe
  • United States
  • Rest of World
  • Scientific Issues
  • Patent Issues
  • Pricing Issues
  • Barriers to Entry
  • Innovator Strategies and Challenges
  • Bulk Suppliers and Contract Manufacturing
  • Bioequivalence Issues
  • International Issues
  • Low Cost Branded hGH

Chapter Six: Market Summary

  • Total Market Size and Forecast
  • Competitive Analysis

Chapter Seven: Company Profiles

  • Analiza, Inc.
  • Apotex, Inc.
  • Barr Laboratories, Inc.
  • BioGeneriX AG
  • BioPartners GmbH
  • Cangene Corporation
  • Dr Reddy’s Laboratories Ltd.
  • Dragon Pharmaceuticals, Inc.
  • GeneMedix plc
  • IVAX Corporation
  • Microbix Biosystems, Inc.
  • Rhein Biotech
  • Sandoz
  • Sicor, Inc.
  • STADA Arzneimittel AG
  • TEVA Pharmaceutical Industries, Ltd.
  • Watson Pharmaceuticals, Inc.

Appendix A: Biogeneric Company Directory

Appendix B: Generic Industry Company Directory

List of Exhibits

Chapter One: Executive Summary

  • Table 1-1: Total World Biogenerics Market Potential 2004-2010
  • Figure 1-1: The World Market Potential for BioGeneric Drugs by Patent Segment 2004-2010
  • Figure 1-2: The World Market Potential for BioGeneric Drugs 2010 Market Share by Current Patent Status

Chapter Two: Introduction and Overview

  • Table 2-1: Scientific Differences of Pharmaceuticals and Biopharmaceuticals

Chapter Three: Market Analysis: Biologics with Currently Expired Patents

  • Table 3-1: Currently Marketed Biopharmaceuticals with Expired Patents (Product, Manufacturer, 2004 Sales, Patent Approval Date, Expiration Date, Known Generic Company Development)
  • Table 3-2: Total World Biogenerics Market Potential for Products with Currently Expired Patents 2004-2010
  • Table 3-3: Total U.S. Biogenerics Market Potential 2004-2010 for Products with Expired Patents
  • Table 3-4: Total Non-U.S. Biogenerics Market Potential 2004-2010 for Products with Expired Patents

Chapter Four: Market Analysis: Biologics with Currently Active Patents

  • Table 4-1: Currently Marketed Biopharmaceuticals with Active Patents (Product, Manufacturer, 2004 Sales, Patent Approval Date, Expiration Date, Known Generic Company Development)
  • Table 4-2: Total World Biogenerics Market Potential for Products with Currently Active Patents 2004-2010
  • Table 4-3: Total U.S. Biogenerics Market Potential for Products with Currently Active Patents 2004-2010
  • Table 4-4: Total Non-U.S. Biogenerics Market Potential for Products with Currently Active Patents 2004-2010

Chapter Five: Issues and Trends

  • Table 5-1: Estimates of Treatment Cost Per Patient of Selected Biopharmaceuticals

Chapter Six: Market Summary

  • Table 6-1: Total World Biogenerics Market Potential 2004-2010
  • Table 6-2: The World Market Potential for BioGeneric Drugs by Patent Segment 2004-2008
  • Figure 6-1: Trending in the World Market Potential for BioGeneric Drugs by Patent Segment by Revenues 2004-2010
  • Figure 6-2: The World Market Potential for BioGeneric Drugs by Segment: Market Share 2010

 

    Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)
    April 11, 2025
    Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)
    February 13, 2025
    Cell and Gene Therapy Deals Analysis, 2021-2024
    June 3, 2024
    Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029
    April 30, 2024

Related products

  • Placeholder image

    Emerging Cancer Vaccine Market, The

    $3,500.00 – $7,000.00
  • Placeholder image

    Early Stage Drug Discovery 2004: Combi-chem & High Throughput Screening Revisited

    $2,995.00 – $5,990.00
  • Placeholder image

    World Market for Anti-infectives Volume II: The World Market for Antibacterial Medications, The

    $2,500.00 – $5,000.00
  • Placeholder image

    World Market for Anti-infectives Series: Volumes I – III – Antifungals, Antibacterials and Antivirals, The

    $6,000.00 – $12,000.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
World Market for Respiratory Equipment, TheAdvanced Drug Delivery – Technologies, Applications, and Markets, 2nd...
Scroll to top